Tigecycline Market by Application 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Tigecycline Market
Tigecycline Market: by Application (Skin & Soft Tissue Infections, Complicated Intra-abdominal Infections, and Community-acquired Bacterial Infection); Target Bacteria Type (Gram Positive and Gram Negative) and Geography – Forecast 2016-2021
Report Code : CMR 0247
Updated Date: 05 February, 2016  

Copies sold

    Client Rating

  • Report Description
  • Table of Contents
  • Customization Options
1. Tigecycline – Market Overview
2. Executive Summary
3. Tigecycline – Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Patent Analysis
      3.2.4. Top 5 Financials Analysis
4. Tigecycline – Market Forces
   4.1. Market Drivers
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the Tigecycline Industry
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers
      4.4.3. Threat of New Entrants
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. Tigecycline Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Suppliers/Distributors Analysis
6. Tigecycline Market – By Applications:
   6.1. Introduction
   6.2. Skin & Soft Tissue Infections,
   6.3. Complicated Intra-abdominal Infections and
   6.4. Community-acquired Bacterial Pneumonia
7. Tigecycline Market - By Target Bacteria Type:
   7.1. Introduction
   7.2. Gram Positive Bacteria and
   7.3. Gram Negative Bacteria
8. Tigecycline Market- By Geography:
   8.1. Introduction
   8.2. North America
      8.2.1. U.S.
      8.2.2. Canada
      8.2.3. Mexico
      8.2.4. Rest of North America
   8.3. Europe
      8.3.1. France
      8.3.2. Germany
      8.3.3. Italy
      8.3.4. Spain
      8.3.5. U.K
      8.3.6. Rest of Europe
   8.4. APAC
      8.4.1. Australia
      8.4.2. China
      8.4.3. India
      8.4.4. Japan
      8.4.5. Rest of APAC
   8.5. ROW
      8.5.1. Middle East & Africa
      8.5.2. South America
9. Market Entropy
   9.1. New Product Launches
   9.2. M&As, Collaborations, JVs and Partnerships
10. Company Profiles
   10.1. Pfizer Inc.,
   10.2. Hisun Pharma,
   10.3. Hansoh Pharma,
   10.4. Jiagsu Aosaikang Pharmaceutical Co. Ltd.,
   10.5. HICIN Pharma,
   10.6. Abbott Laboratories,
   10.7. Amgen,
   10.8. Astrazeneca,
   10.9. Merck,
   10.10. Novartis,
   10.11. Roche Holdings,
   10.12. Johnson & Johnson,
   10.13. Sanofi SA,
   10.14. Lifecare Innovations Pvt. Ltd. and
   10.15. Progen Nutraceuticals Pvt. Ltd.
*More than 10 Companies are profiled in this Research Report*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Tigecycline is a broad spectrum glycylcycline type acting as a protein synthesis inhibitor. Tigecycline blocks the interaction of aminoacyl-tRNA with the A site of the ribosome by binding to the 30S ribosomal subunit of bacteria and thus exhibits bacteriostatic activity. Additionally, Tigecycline is shown to exhibit bactericidal activity against isolates of L. pneumophila and S. pneumoniae.

Tigecycline is used to treat a variety of bacterial infections and thus acts as an antibiotic. Tigecycline is a first glycylcycline type that is administered intravenously. The main reason for the discovery of Tigecycline is the rising rate of antibiotic resistance in a number of bacteria such as Acinetobacter baumannii, Staphylococcus aureus, and E. coli. Tigecycline is a tetracycline derivative antibiotic and thus its structural modifications have extended its therapeutic activity to include Gram-negative and Gram-positive bacteria, comprising those of multi-drug resistance. The increasing demand for Tigecycline as an antibiotic is expected to fuel the market growth over the forecast period.

Tigecycline is recommended by the European Society of Clinical Microbiology and Infection as a potential salvage therapy for complicated and severe refractory Clostridium difficile infection. Tigecycline also finds application in treatment of immune-compromised patients or patients having cancer. Even more, tigecycline have potential for use in acute myeloid leukemia. Tigecycline is prescribed at every 12 hours with slow intravenous infusion. Patients suffering with impaired liver function needs to be prescribed a lower dose of tigecycline. No adjustments are needed for patients suffering with impaired kidney function.

The global Tigecycline market is classified into applications as Skin & Soft-tissue Infections, Complicated Intra-abdominal Infections and Community-acquired Bacterial Pneumonia. In addition, the global Tigecycline market is further bifurcated on the basis of target bacteria type into Gram Positive Bacteria and Gram Negative Bacteria.

Lastly, the global tigecycline market is bifurcated by regions as North America, Asia Pacific (APAC), Europe and Rest of the World (RoW). Presently, the global tigecycline market is dominated by Asia-Pacific region primarily due to a significant adoption of tigecycline as an antibiotic in pharmaceuticals industry. The APC region is also expected to continue its dominance in the market during the forecast period. The European and North American regions are also analyzed to witness a healthy growth rate in the global tigecycline market during the forecast period.

Tigecycline Market

Sample Companies Profiled in this Report are:
  • Pfizer Inc. (U.S.)
  • Hisun Pharma (U.S.)
  • Hansoh Pharma (China)
  • Jiagsu Aosaikang Pharmaceutical Co. Ltd. (China)
  • Abbott Laboratories (U.S.)
  • 10+.
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports